Brief: Adaptive Biotech Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Mln
12/09/2022 13:41
Sept 12 (Reuters) - Adaptive Biotechnologies Corp ADPT.O :
* ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NON-DILUTIVE ROYALTY
FINANCING WITH ORBIMED FOR UP TO $250 MILLION
* ADAPTIVE - ORBIMED TO BE ENTITLED TO RECEIVE 5% OF CO'S
GAAP
REVENUES, INCREASING TO 8% & 10% IF SECOND & THIRD TRANCHES ARE
DRAWN, RESPECTIVELY
Source text for Eikon: ID:nGNX5Nh5C5
Further company coverage: ADPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptive Biotechnologies
See all newsBrief: Adaptive Biotechnologies Corp - Issues $345 Million In 0% Convertible Senior Notes Due 2031 - SEC Filing
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, CME
U.S. STOCKS ON THE MOVE-Intel, La-Z-Boy, AST SpaceMobile